Introduction to the field of microbiome research {#s02}
================================================

Over evolutionary time, humans have developed symbiotically with a diversity of environmental microbial species ([@bib196]). Appreciation of the diversity of human-associated microbes, their functional gene capacity, and the breadth of biochemicals they generate in and on the human body has only relatively recently been appreciated, in large part due to advances in next-generation, high-throughput sequencing and mass-spectrometry platforms ([Fig. 1](#fig1){ref-type="fig"}). Sequencing platforms permit assessment of microbiota composition via biomarker gene sequencing, for example, sequencing and classification of 16S ribosomal RNA or the interspacer region amplicon pools to assess the identity and distribution of bacteria or fungi, respectively. These communities may then be interrogated to identify signature microbiota features associated with indications of interest. As the field moves toward a functional understanding of the human microbiome, efforts to investigate the functional gene capacity and transcriptional activity of microbiomes have advanced via shotgun sequencing of extracted DNA (metagenomics) or RNA (metatranscriptomics/RNA Seq), respectively. In parallel, detection and identification of microbiome-associated products, including metabolites and proteins, have been facilitated by targeted and untargeted mass spectrometry. These advances in high-throughput technologies have not only facilitated analyses of the composition and function of human-associated microbiomes, but they have also begun to reveal a diverse array of microbial-derived products that facilitate interspecies interactions in the human host ([@bib175]; [@bib42]).

![**Tools for analyses of the human gut microbiome.** Microbiome studies are facilitated by next-generation sequencing (NGS) and liquid/gas chromatography (LC/GC) mass spectrometry (MS) platforms that permit analysis of composition, function, and productivity of the microbiome. Ideally, these approaches are applied in parallelto provide the most comprehensive view of host microbiomes.](JEM_20180448_Fig1){#fig1}

Niche specificity of the microbiome {#s03}
===================================

Through the application of high-throughput assays, it has become apparent that the healthy human superorganism comprises a series of niche-specific microbiomes across distinct body habitats ([@bib45]; [@bib31]). On the skin, for example, factors such as substrate and water availability as well as pH strongly correlate with the presence of habitat-specific microbiome compositions that are relatively consistent across healthy individuals ([@bib152]). This is also true of the gastrointestinal (GI) tract, where distinct microbiome assemblies exist in various intestinal compartments ([@bib55]). According to a recent study of infant microbiome development at multiple body sites, microbial niche specificity is evident as early as 6 wk of age ([@bib38]), implicating early life factors in shaping niche-specific microbial assembly in infancy. Among the factors influencing early-life microbiome assembly is pioneer microbial colonization, which likely influences niche-specific microbiome development via local nutrient utilization and/or production of molecules that dictate interspecies compatibility and competitive colonization ([@bib131]; [@bib230]; [@bib65]).

Microbes are masters at sensing and responding to their environment; this is achieved via production of a range of biochemicals, from small diffusible quorum-sensing molecules that facilitate microbe--microbe--host communications ([@bib183]; [@bib158]) to complex natural products such as macrolides and polyketides, many of which have potent antimicrobial and immunomodulatory activities ([@bib56]). This biochemical arsenal facilitates microbial competitive colonization, selective inclusion or exclusion, and modification of the activities of other species in the local environment ([@bib63]; [@bib170]; [@bib216]). This concept was elegantly demonstrated in a recent study in which oral supplementation of antimicrobial-treated mice with a consortium of four bacterial species (*Bacteroides sartorii*, *Parabacteroides distasonis*, and *Clostridium* cluster XIVa members *Clostridium bolteae* and *Blautia producta*) prevented colonization by vancomycin-resistant *Enterococcus faecium* (VRE; [@bib28]). Critically, multilevel cooperation between bacterial species within this consortium was necessary to support colonization of the murine intestine with *B. producta*, the species that directly inhibited growth of pathogenic VRE. Such instances of microbial competitive colonization may be enhanced by microbial manipulation of host immunity, which acts as a reinforcing selective pressure on microbes in a given niche. Indeed, a recent study of the skin microbiota supports this concept; early life introduction of *Staphylococcus epidermidis* to the developing hair follicles of mice induced a wave of regulatory T (T reg) cells ([@bib184], [@bib185]) and facilitated competitive colonization by *S. epidermidis* to the exclusion of other bacterial species ([@bib147]; [@bib148]). In healthy humans, relatively stable, niche-specific microbiomes have been described ([@bib152]; [@bib55]; [@bib165]), reinforcing the notion that local microenvironmental conditions, and perhaps a small number of keystone organisms that induce specific nutritional and/or immunological conditions at distinct body sites, promote niche-specialized microbiomes.

Variability of the gut microbiome {#s04}
=================================

Although at higher levels of classification, distributions of organisms at specific body sites are highly conserved, there remains a high degree of interindividual variability at the species and strain level---an important feature rarely captured in biomarker-based microbiota profiling studies. Several studies have reported associations between host genetics and the microbiome ([@bib17]; [@bib19]; [@bib225]). In mice, the relationships between host genotype and the gut microbiota have been demonstrated in genetically distinct mouse strains, in which independent quantitative trait loci analysis revealed 169 joint quantitative trait loci intervals that were significantly associated with the abundance of specific microbial taxa in the gut ([@bib203]). However, in humans, the relationship between host genotype and the microbiota appears less strong. While there is relatively greater similarity in microbial community membership within the intestinal microbiome among family members ([@bib189]; [@bib113]) and in monozygotic, compared with dizygotic, twins ([@bib80]), this relative similarity may be confounded by common environmental exposures. Indeed, divergence of microbial functional modules in the gut microbiota ([@bib242]), in parallel with changes in immune status ([@bib24]), have been observed when monozygotic twins reside in distinct environments. A more recent study of \>1,000 subjects corroborated this observation by demonstrating that environmental exposures, including diet, dominate genetic factors in shaping gut microbiota ([@bib177]). Moreover, inclusion of microbial factors improved prediction accuracy for many host traits, including glucose and obesity measures, compared with models that exclusively used host genetics and environmental data ([@bib177]). Thus, combinatorial algorithms that consider microbial and host genetics in addition to environmental exposures may offer the most prediction accuracy for a range of host traits.

The influence of diet on microbiota composition and function is well established ([@bib50]; [@bib52]; [@bib206]; [@bib240]; [@bib101]). Beyond diet, a number of other factors have been associated with variability in microbiota composition or function, including sex hormones ([@bib69]), treatment with antibacterial or antifungal agents ([@bib171]; [@bib238]), pharmaceuticals such as proton pump inhibitors ([@bib92]), xenobiotics ([@bib140]), environmental toxicants ([@bib133]; [@bib5]), and the number of prescription drugs consumed ([@bib218]). Emerging evidence suggests that these factors collectively shape the gut microbiome throughout an individual's lifespan, resulting in a unique and personalized microbial fingerprint ([@bib70]).

Development of the human gut microbiome {#s05}
=======================================

There is growing evidence that exposure to microbes begins in utero, based on studies using DNA-based assays that detected bacteria in placental material ([@bib1]), amniotic fluid ([@bib43]), and meconium, which forms in utero ([@bib82]; [@bib146]; [@bib58]; [@bib65]). Although these studies are limited by the fact that DNA-based assays do not provide evidence of viable microbial cells, they offer initial indications that human--microbial encounters commence during gestation. Following delivery, the repertoire of bacteria ([@bib246]; [@bib58]; [@bib209]) and both prokaryotic and eukaryotic viruses ([@bib128]) expands, increasing the functional gene capacity of the gut microbiome. In parallel, fungal diversity contracts, likely owing to unfavorable selective pressures in the developing gut ([@bib73]). A number of factors, including the mode of delivery ([@bib13]; [@bib120]; [@bib113]), early-life diet ([@bib13]; [@bib18]; [@bib208]), antibiotic use ([@bib18]), pet exposure ([@bib73]; [@bib120]; [@bib58]), sex ([@bib73]), and maternal health ([@bib38]; [@bib58]; [@bib209]) have been linked to distinct gut microbiome compositions at discrete time points and to variation in microbial successional trajectories during this critical window of development ([Fig. 2](#fig2){ref-type="fig"}). Evidence that these early-life microbial colonization patterns and successional trajectories are relevant for subsequent health outcomes is growing. For example, 1-mo-old infants with altered microbiota composition and metabolic function were found to be at significantly higher risk of developing atopy (allergic sensitization) and asthma in childhood ([@bib73]). In addition, delayed gut microbiome diversification over the first year of life has been linked to allergy, asthma ([@bib58]; [@bib209]), and malnutrition ([@bib211]).

![**The infant gut bacterial microbiome rapidly diversifies over the first year of life in healthy infants but is delayed in those who develop allergy or asthma or who are malnourished.** A number of pre-, peri-, and postnatal environmental exposures are known to modulate risk for childhood disease, e.g., formula feeding, antimicrobial use, and exposure to environmental tobacco smoke (ETS) or animals. These same exposures also relate to gut microbiome composition at discrete developmental time points and to successional trajectories in early life.](JEM_20180448_Fig2){#fig2}

The rapid expansion of bacterial diversity observed in the first year of life slows considerably by 3 yr of age ([@bib246]; [@bib228]), and by 5 yr of age the composition of the gut microbiome becomes more stable, attributable, at least in part, to a large proportion of stably maintained *Bacteroides.* Nonetheless, the gut microbiome in children is less diverse and functionally distinct from that of healthy adults ([@bib36]). Gut microbiota complexity (number of taxa and functional genes) typically reaches adult levels by preadolescence (7--12 yr of age), but microbial communities at this age remain taxonomically and functionally distinct from those of adults, with relatively lower levels of *Bacteroides* and higher levels of *Bifidobacterium* ([@bib86]).

In adulthood, despite the taxonomic uniqueness and personal nature of the human gut microbiome ([@bib62]), its functional attributes are relatively consistent across healthy adult populations ([@bib224]). Some of the core functional pathways in the adult gut microbiome include those involved in carbohydrate and amino acid metabolism, fermentation, and oxidative phosphorylation ([@bib224]; [@bib166]; [@bib246]). In the elderly, gut microbiomes become compositionally unstable and less diverse ([@bib151]), a phenomenon that has been linked with increasing frailty ([@bib95]) and declining immune function ([@bib41]). In older populations, low gut microbiota richness, a proxy for loss of microbial species and their repertoire of functional genes, appears to be a predictor of mortality ([@bib218]), whereas enrichment of certain bacteria, including *Akkermansia* and *Bifidobacterium*, is associated with longevity ([@bib16]). A direct link between age-related gut microbiota changes and age-associated systemic inflammation has been established in a recent study, in which cohousing germ-free (GF) mice with old, but not young, microbiome-replete mice increased intestinal permeability and age-related inflammation ([@bib215]). Thus, the evidence to date indicates that age-associated changes in the gut microbiome parallel fluctuations in immune status ([@bib199]), and this represents an important consideration in studies evaluating human health or when considering microbiota manipulation for prevention or treatment of specific illnesses.

The gut microbiome in immunity and homeostasis {#s06}
==============================================

In healthy humans, the gut microbiome has coevolved to exist in a state of mutually beneficial symbiosis with its host ([Fig. 3](#fig3){ref-type="fig"}) and encodes a breadth of functional genes that dwarfs that of the human genome. A study cataloging functional genes in the human gut microbiome identified as many as 9.9 million unique microbial genes across 1,200 healthy subjects on three different continents ([@bib123]). Among the established microbial functions known to be expressed by human gut microbiomes are catalytic pathways for the metabolism of complex carbohydrates that produce short chain fatty acids (SCFAs; [Table 1](#tbl1){ref-type="table"}), anti-inflammatory, anti-proliferative lipids that represent an essential energy source for GI epithelial cells ([@bib105]). Other microbial-derived bioactive metabolites include essential vitamins, such as K ([@bib103]) and B ([@bib135]); hormones ([@bib246]; [@bib244]); neurological signaling molecules, such as serotonin ([@bib245]; [@bib174]), which may be derived via microbial metabolism of tryptophan ([Table 1](#tbl1){ref-type="table"}); and a large suite of other natural products, many of which have as-yet-undefined functions ([@bib56]; [@bib83]). Given the increasing appreciation for the diversity of functional genes encoded and bioactive biochemicals produced by the mammalian coevolved gut microbiome, it is unsurprising that critical aspects of physiological development have been linked to the microbiome. Indeed, juvenile GF mice commonly exhibit stunted growth and reduced somatotropic insulin-like growth factor 1 (IGF1) activity, which is restored by GI colonization by commensal bacteria ([@bib193]).

![**In healthy adults, the gut microbiome exists in a state of mutual symbiosis with its host.** The environment of the gut dictates both the composition and functional productivity of the adult gut microbiota, which may interact with the host through presentation of various ligands such as pathogen-associated molecular patterns (PAMPs) and production of metabolites, e.g., SCFAs. These molecules modulate immune homeostasis in the GI tract and at remote mucosal surfaces and organs via their entry into the circulation.](JEM_20180448_Fig3){#fig3}

###### Examples of gut microbiota--derived metabolites and their beneficial effects on human health

  Metabolite/pathway                                                                  Microbial agent                                                                                                  Health benefits
  ----------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------
  Butyrate (carbohydrate metabolism)                                                  *Clostridia* (clusters IV and XIVa)                                                                              Increased intestinal barrier function ([@bib105]; [@bib253])
  *F. prausnitzii*                                                                    Modulate intestinal macrophage function ([@bib35])                                                               
  *Eubacterium* spp.                                                                  Regulation of colonic T reg cell homeostasis ([@bib75]; [@bib202])                                               
  *Roseburia* spp.                                                                    Induction of tolerogenic DCs that polarize naive CD4^+^ T cells toward IL-10--producing T reg cells ([@bib99])   
  *Coprococcus catus*                                                                 Suppression of colonic inflammation ([@bib200]; [@bib198])                                                       
  *Anaerostipes hadrus*                                                               Improvements in insulin sensitivity ([@bib107])                                                                  
  Propionate (carbohydrate metabolism)                                                *Bacteroides* spp.                                                                                               Regulation of colonic T reg cell homeostasis ([@bib75]; [@bib202])
  *Blautia obeum*                                                                     Suppression of colonic inflammation ([@bib219])                                                                  
  *C. catus*                                                                          Decreased innate immune responses to microbial stimulation ([@bib40])                                            
  *Roseburia inulinivorans*                                                           Protection from allergic airway inflammation ([@bib223])                                                         
  *P. copri*                                                                          Improvements in insulin sensitivity and weight control in obese mice ([@bib51])                                  
  *Alistipes putredinis*                                                                                                                                                                               
  *Dialister invisus*                                                                                                                                                                                  
  *A. muciniphila*                                                                                                                                                                                     
  *Eubacterium hallii*                                                                                                                                                                                 
  Indole (tryptophan metabolism)                                                      A variety of bacteria possessing tryptophanase, including:                                                       
  *Lactobacillus* spp.                                                                Maintenance of host--microbe homeostasis at mucosal surfaces via IL-22 ([@bib248])                               
  *B. longum*                                                                         Increased barrier function ([@bib14])                                                                            
  *B. fragilis*                                                                       Modulation of host metabolism ([@bib37])                                                                         
  *P. distasonis*                                                                                                                                                                                      
  *Clostridium bartlettii*                                                                                                                                                                             
  *E. hallii*                                                                                                                                                                                          
  *E. coli*                                                                                                                                                                                            
  I3A (tryptophan metabolism)                                                         *Lactobacillus* spp.                                                                                             Maintenance of mucosal homeostasis and intestinal barrier function via increased IL-22 production ([@bib248])
  Protection against intestinal inflammation in mouse models of colitis ([@bib116])                                                                                                                    
  IPA (tryptophan metabolism)                                                         *Clostridium sporogenes*                                                                                         Maintenance of intestinal barrier function and mucosal homeostasis ([@bib229])
  Increased production of antioxidant and neuroprotectant products ([@bib91])                                                                                                                          
  HYA (lipid metabolism)                                                              *Lactobacillus* spp.                                                                                             Maintenance of intestinal barrier function ([@bib143])
  Decreased inflammation ([@bib98])                                                                                                                                                                    
  Increased intestinal IgA production ([@bib98])                                                                                                                                                       
  CLA (lipid metabolism)                                                              *Lactobacillus* spp.                                                                                             Decreased inflammation ([@bib231])
  *Bifidobacterium* spp.                                                              Reduced adiposity ([@bib195])                                                                                    
  *F. prausnitzii*                                                                    Improved insulin sensitivity ([@bib76])                                                                          

CLA, conjugated linoleic acid; HYA, 10-hydroxy-cis-12-octadecoate (linoleic acid derivative); I3A, indole-3-aldehyde; IPA, indole-3-propionate.

Of equal importance to the microbiome's effects on host physiology is its role in the development and maintenance of local ([@bib87]; [@bib121]) and systemic innate and adaptive immune function ([@bib187]). Immune dysfunction is increasingly identified as a component of a range of chronic diseases, including obesity ([@bib239]), metabolic syndrome ([@bib172]), multiple sclerosis (MS; [@bib100]), and autism spectrum disorders (ASD; [@bib32]), among others. Notably, all of these disorders have also been shown to associate with perturbations of the gut microbiome, generally associated with loss of microbial diversity and, particularly, with depletion of specific bacteria, including *Akkermansia* and *Faecalibacterium*, that are thought to promote immune tolerance ([@bib204]; [@bib190]; [@bib176]; [@bib154]). Evidence for the key role of microbes in shaping immune function is illustrated in studies of GF mice, which have underdeveloped innate and adaptive immune systems ([@bib108]) and reduced expression of antimicrobial peptides ([@bib149]) and IgA ([@bib84]) necessary for clearance of pathogenic microbes from the gut lumen ([@bib144]). Additionally, GF animals possess fewer T reg cells ([@bib11]; [@bib153]), lack regulatory gut CD4^+^CD8αα^+^ double-positive intra-epithelial lymphocytes ([@bib34]), have compromised innate lymphoid cell function ([@bib85]), and are more susceptible to microbial infections. Thus, the confluence of data from human and murine studies indicates that the gut microbiome plays a key role in promoting appropriate physiological and immune development.

Both the diversity and redundancy in immune system activation by human gut microbial symbionts is well accepted ([@bib78]). A variety of gut bacteria, including *Bifidobacterium adolescentis* and segmented filamentous bacteria, have been identified as key modulators of GI T helper 17 (Th17) cells ([@bib94]; [@bib212]; [@bib78]), instrumental in the maintenance of barrier function and protection against pathogenic microbes ([@bib157]; [@bib236]). *Clostridium* species, including those belonging to clusters IV, XIVa, and XVIII, induce CD4^+^Foxp3^+^ T reg cells, via production of SCFAs ([@bib12]; [@bib194]; [@bib78]). Surface polysaccharide A of *Bacteroides fragilis* has been shown to bind to Toll-like receptor 2 on dendritic cells (DCs), which then induce the production of the anti-inflammatory cytokine IL-10 by T reg cells ([@bib49]) and promote immune tolerance ([@bib7]). Although the field is still nascent, it is already clear that a broad range of microbial species and their associated products modulate discrete features of adaptive and innate immunity, which offers a novel opportunity for microbial-based approaches for prevention or treatment of inflammatory conditions.

Early-life microbiome and immune maturation {#s07}
-------------------------------------------

The evidence that microbes are important symbiotic modulators of physiological, metabolic, and immunological function in the mammalian host has expanded over the past decade ([@bib132]). Thus, the early-life gut microbiome has formed the focus of intense research ([@bib39]; [@bib191]; [@bib77]; [@bib65]; [@bib156]). Recent data indicate that the developing gut microbiota of human infants affects the progression of intestinal mucosal IgA responses ([@bib162]), and perturbations to these nascent microbial communities cause long-lasting metabolic and immunological dysregulation ([@bib180]; [@bib134]). For instance, macrolide treatment of conventional, neonatal mice perturbs their gut microbiota, with depletion of *Bifidobacterium* and segmented filamentous bacteria, resulting in decreased numbers of intestinal CD4^+^IL-17A^+^ lymphocytes and fecal IgA concentrations, persistent features not observed in neonatal GF or conventional adult mice ([@bib180]).

Development of the gut microbiome in early life appears to adhere to ecological principles of primary succession, in which the initial (pioneer) organisms colonize a previously pristine habitat, influence ecosystem conditions, and dictate subsequent accumulation of species in the niche via competitive colonization. Initial colonization by distinct microbial species in the nascent human gut may thereby induce discrete immune and physiological conditions ([Fig. 2](#fig2){ref-type="fig"}) that affect health outcomes later in life. Support for this concept comes from recent studies showing, for example, that risk of childhood atopy and asthma was linked to the composition and metabolic activity of the gut microbiome at 1 mo of age ([@bib73]). Longitudinal birth cohort studies, such as a large study of Swedish mother--infant dyads, have also indicated that infants delivered by cesarean section and formula-fed in early life exhibit distinct neonatal gut microbiome features that persist throughout the first year of life ([@bib13]) and significantly reduce vertical transmission ([@bib113]) compared with infants born vaginally. The observation that cesarean section and formula-fed babies develop along a distinct microbial successional trajectory suggests that founder microbial populations that develop in utero could be usurped by more competitive microbial strains encountered in early postnatal life, whose colonization is reinforced by the selective effects of diet. Likewise, babies at high risk for asthma development exhibit distinct bacterial microbiota in their meconium and delayed diversification of their gut microbiota over the first year of life ([@bib58]). Encouragingly, this delayed diversification was partially remedied with daily, postpartum *Lactobacillus rhamnosus* supplementation, which was associated with a restructured gut microbiota composition and metabolic output more consistent with that of low-risk infants ([@bib58]), providing evidence that gut microbiota development and metabolism may be reengineered via microbial intervention. However, this commercially available probiotic does not engraft in the human gut microbiome, and the beneficial effects of supplementation were lost upon cessation of probiotic administration. Although a relatively new concept in terms of applicability to the human microbiome, recent data in the field suggest that ecological principles may offer a useful theoretical framework to understand human microbiome development in early life. Improved understanding of microbial competitive colonization, engraftment, and succession during specific stages of human development may inform rational design of microbiome-targeted therapeutics aimed at reengineering microbial community composition and metabolic output, and ultimately at preventing chronic disease in later life.

Microbiome perturbations, immune dysfunction, and chronic disease {#s08}
=================================================================

Inflammatory bowel disease (IBD) {#s09}
--------------------------------

Perturbations to the composition and function of bacterial and fungal gut microbiota have been implicated in various forms of IBD, including Crohn's disease (CD) and ulcerative colitis (UC; [@bib204], [@bib205]; [@bib115]; [@bib116]; [@bib137]; [@bib188]). Both conditions exhibit loss of enteric bacterial diversity ([@bib79]; [@bib137]) and expansion of specific bacterial clades such as *Enterobacteriaceae* ([@bib79]). Expansion of *Enterobacteriaceae* has been associated with new-onset CD, and targeted depletion of this bacterial family ameliorates intestinal inflammation in mice ([@bib255]). Additionally, loss of certain symbiotic taxa such as *Faecalibacterium prausnitzii* has been related to recurrence of CD, and supplementation of mice with this organism reduced inflammation in a model of chemically induced colitis ([@bib204]), suggesting an anti-inflammatory role for this mucosal-associated enteric symbiont. More recently, a bioactive microbial anti-inflammatory molecule was identified in supernatant of cultured *F. prausnitzii* ([@bib168]) and is thought to be responsible, at least partly, for reducing intestinal inflammation. Indeed, supplementing mice with *Lactococcus lactis* expressing the *F. prausnitzii* microbial anti-inflammatory molecule alleviated intestinal inflammation ([@bib168]; [@bib22]). A number of studies have indicated that helminth infection abrogates IBD ([@bib23]), including one study showing that helminth infection promotes the diversification of gut microbiota and enrichment of anti-inflammatory Clostridiales in mice genetically predisposed to disease ([@bib169]). Although there is limited evidence that helminth introduction ameliorates IBD in humans, these observations support the concept that enteric bacterial microbiota manipulation holds potential for the management or prevention of IBD.

Microbial-derived products found in stool of patients with UC have been shown to promote inflammation. Human DCs stimulated with fecal water from the stool of patients with UC increased the ratio of Th2 to Th1 cells upon coculture with autologous naive T cells ([@bib137]). The degree of Th2 induction was related to the specific fecal microbiota composition and to the degree of disease severity ([@bib137]). Specifically, microbiota associated with the most severely ill patients exhibited expansions of *Bacteroides* and *Candida* ([@bib137]), which were associated with a distinct profile of microbial ligands and metabolic products in the fecal microbiome of these patients. Additionally, independent studies have indicated that both the gut microbiota of patients with IBD and that of colitis-susceptible Card9^−/−^ mice exhibit reductions in the concentration of tryptophan-derived indole derivatives that act as aryl hydrocarbon receptor ligands and promote IL-22 production ([@bib119]; [@bib116]). Transfer of feces from IL-22^−/−^ ([@bib249]) or Card9^−/−^ mice to wild-type GF recipients increased their susceptibility to colitis ([@bib116]), and supplementation with three *Lactobacillus* strains capable of metabolizing tryptophan, or treatment with an aryl hydrocarbon receptor agonist, restored intestinal IL-22 production and attenuated intestinal inflammation ([@bib116]). The protective effect of *Lactobacillus* was also observed in another experimental model of colitis, in which *Lactobacillus murinus* enrichment was associated with expansion of T reg cells and protection ([@bib213]). Hence dysbiosis associated with loss of intestinal bacteria capable of modulating intestinal inflammation further suggests that microbiome manipulation, particularly supplementation with strains that restore depleted microbial functions in diseased patients, represents a plausible avenue of therapeutic intervention.

Persistent antibiotic-induced colitis {#s10}
-------------------------------------

Antibiotic-induced alterations in the gut microbiome and its associated metabolome reduce colonization resistance against the spore-forming, toxin-producing pathogen *Clostridium difficile* ([@bib214]), a causative agent of antibiotic-associated colitis. Germination and overgrowth of this pathogen are thought to be facilitated by a reduction of microbiota-derived secondary bile acid metabolites that inhibit spore germination ([@bib26]). Using mathematical modeling guided by analysis of the microbiota of hospitalized patients, a recent study identified *Clostridium scindens* as an intestinal bacterial species that dehydroxylates bile acid 7α, thereby mediating colonization resistance against *C. difficile* ([@bib26]). These results are encouraging first steps for exploring novel preventive strategies, such as prophylactic microbial-based supplements, for populations at risk of developing antibiotic-associated colitis.

Atopic asthma {#s11}
-------------

The rapid increase in asthma prevalence in industrialized nations over the past several decades, particularly among pediatric populations, cannot be explained by genetic risk factors alone and is thought to be related to altered environmental exposures associated with Western lifestyles. A number of validated epidemiological observations have implicated early life environmental exposures in increased risk for childhood asthma. Many of these exposures are known to shape the nascent gut microbiome, including cesarean birth ([@bib53]; [@bib96]; [@bib13]; [@bib208]; [@bib38]), antimicrobial administration ([@bib97]; [@bib112]; [@bib2]; [@bib243]), formula feeding, exposure to furred pets, and environmental toxins ([@bib120]; [@bib150]).

Further evidence for an intricate relationship between environmental exposure, the gut microbiome, and allergic airway disease comes from an expanding body of work ([@bib71]; [@bib57]), particularly those utilizing experimental animal models. For example, treating neonatal mice with vancomycin was shown to diminish gut microbial diversity, alter metabolite profiles, exacerbate Th2 responses, and increase susceptibility to allergic lung inflammation ([@bib181]; [@bib30]). Supplementation with SCFAs ameliorated airway inflammation in these mice, with the mechanism attributed to decreased activity of T cells and DCs, decreased numbers of IL-4--producing CD4^+^ T cells, and reduced levels of circulating IgE ([@bib30]). Oral supplementation of mice with house dust from homes with dogs also reduced allergic airway sensitization to cockroach antigen ([@bib72]), consistent with the observation that children who grow up with dogs are less likely to develop atopy ([@bib155]). The gut microbiota in mice treated with dog-associated house dust was found to be enriched with *Lactobacillus johnsonii*, and oral supplementation with this species protected mice against airway allergen challenge and respiratory viral infection, with reduced airway concentrations of IL-4, IL-5, IL-13, and IL-17 and increased numbers of T reg cells ([@bib72]). More recently, protection mediated by oral *L. johnsonii* supplementation was linked to alterations in circulating immunomodulatory metabolites, including anti-inflammatory ω-3 fatty acids, such as docosahexanoic acid ([@bib67]). That study attributed protection in part to reduced activation of DCs, as DCs exposed to serum from *Lactobacillus*-supplemented, respiratory syncytial virus--infected mice (or to docosahexanoic acid) dampened cytokine production by the DCs upon viral infection ([@bib67]). Reduced allergic airway inflammation is also seen in mice fed a high-fiber diet, which is exclusively metabolized by microbes to produce SCFAs, with evidence for functional reprogramming of hematopoietic cells ([@bib223]). Collectively, these observations indicate that the gut microbiome is plastic and that its related metabolic products have the capacity to suppress inflammation at distal mucosal sites, such as the lungs, and to reprogram bone marrow--derived immune cells.

Early-life microbiota dysbiosis has also been observed in infants at risk for asthma development later in life. Bacterial depletion and fungal expansion were observed in the gut microbiome of at-risk infants at 1 mo of age, with a fecal metabolic profile characterized by depletion of ω-3 fatty acids and prostaglandin precursors ([@bib73]). The soluble products of the gut microbiota from these high-risk infants induced Th2 cell expansion, increased IL-4 expression, and decreased T reg cell populations ex vivo, the latter attributed in part to enrichment of the oxylipin, 12,-13-DiHOME ([@bib73]). The concept that microbial products associated with a disease-susceptible microbiome drive heritable immune dysfunction was supported by a study showing that fecal microbiota transfer from infants at high risk for asthma into GF mice resulted in exacerbated allergic lung inflammation in their adult offspring ([@bib10]). Lung inflammation was alleviated when the offspring mice were supplemented with bacterial taxa depleted in the microbiota of high-risk infants, suggesting a causal role of these bacteria in averting allergic inflammation ([@bib10]).

Observations from independent, geographically distinct birth cohorts encompassing various socioeconomic and racial groups consistently report depletion of symbiotic bacterial taxa, such as *Faecalibacterium*, *Akkermansia*, and *Lachnospira*, in infants at risk of developing atopy or asthma ([@bib10]; [@bib73]; [@bib58]; [@bib209]). These studies add to the mounting evidence that the early-life gut microbiome contributes to risk of childhood asthma development, highlighting the neonatal period as an opportune time for preventive microbial interventions in high-risk infants.

Behavioral disorders {#s12}
--------------------

The gut microbiota has recently emerged as an important mediator of biochemical signaling between the GI tract and the central nervous system, more commonly referred to as the gut--brain axis ([@bib74]). As such, a number of behavioral disorders have been associated with perturbed enteric microbiota, including ASD in children ([@bib125]; [@bib210]). ASD-associated gut microbiota exhibit increased bacterial diversity ([@bib66]) and enrichment of *Collinsella*, *Corynebacterium*, and *Lactobacillus* and the fungal pathobiont *Candida* relative to unaffected siblings ([@bib210]). These microbial perturbations are associated with an altered fermentative profile, with significantly higher concentrations of SCFAs and ammonia ([@bib233]), metabolites that at high concentrations are considered neurotoxic and may promote the adverse neurological effects associated with ASD ([@bib145]).

Given that gut microbiota development in infancy has been linked to maternal health ([@bib38]; [@bib58]; [@bib209]), it is perhaps unsurprising that maternal immune activation ([@bib88]; [@bib25]; [@bib118]; [@bib109]) and obesity ([@bib27]) during pregnancy are associated with features of ASD in offspring, with murine studies suggesting that these processes are governed by the maternal intestinal microbiota ([@bib109]). Feeding pregnant mice a high-fat diet (HFD) induces behavioral alterations in their offspring, in which a number of bacterial taxa including *Lactobacillus reuteri* are depleted from the gut microbiota, and levels of oxytocin in the hypothalamus are decreased ([@bib27]). These behavioral changes could be reversed by cohousing the affected mice with those fed a regular diet or by supplementing them with *L. reuteri* ([@bib27]), a species that promotes oxytocin levels ([@bib164]).

Chronic stress, which is associated with despair behavior in mice, also alters gut microbiota composition. Chronically stressed mice show reduced fecal peroxide levels, *L. reuteri* depletion in their microbiota, and profound changes in serum metabolites, particularly those involved in the tryptophan--kynurenine metabolism pathway ([@bib138]). These mice also have increased intestinal expression of IDO1, the main enzyme responsible for metabolizing tryptophan to kynurenine and thus preventing its conversion to serotonin. Supplementation with *L. reuteri* relieved signs of depression and restored fecal peroxide levels in stressed animals ([@bib138]). An exploratory study in which fecal transfer was used to restore the perturbed gut microbiota in children with ASD showed promising improvements in GI and behavioral symptoms ([@bib102]), although these effects need to be validated in larger trials. Collectively, these findings point to an important role for the gut microbiota in neuro-behavioral modulation and hint at the potential efficacy of microbial restoration as a means of treating or preventing behavioral disorders. However, much more work is needed to elucidate the underlying mechanisms before manipulation of the gut microbiota can be considered for prevention or management of these disorders.

Obesity and type 2 diabetes mellitus (T2DM) {#s13}
-------------------------------------------

Obesity and T2DM are interrelated and associated with dysbiotic gut microbiota ([@bib167]; [@bib104]; [@bib117]; [@bib68]) and with significantly reduced bacterial complexity ([@bib224]; [@bib104]; [@bib117]). A decrease in the relative abundance of *Bacteroides* spp. is particularly striking in obesity ([@bib122]; [@bib8]). A causal role for the gut microbiome in obesity is supported by studies showing that GF mice reconstituted with feces from monozygotic twins discordant for obesity recapitulates the metabolic phenotype (including obesity status) of the donor ([@bib173]). Bacterial species (specifically *Bacteroides* spp.) associated with the lean phenotype seemed to dominate over those associated with obesity, as cohousing mice harboring "lean" microbiota with those harboring "obese" microbiota prevented weight gain and obesity-associated metabolic phenotypes in the latter. Similarly, transplantation of fecal microbiota from healthy lean donors to obese patients resulted in improved insulin sensitivity ([@bib232]). Insulin resistance has been linked to differences in the gut microbiome and microbe-associated increases in serum concentrations of branched-chain amino acids ([@bib160]).

Conversely, an abundance of a mucin-degrading gut bacteria, *Akkermansia muciniphila*, is associated with increased metabolic health in obese patients ([@bib48]) and in mice fed a HFD ([@bib190]). Supplementation with *A. muciniphila* of HFD-induced obese mice reduced circulating LPS levels, enhanced lipid oxidation ([@bib61]), improved glucose tolerance, and reduced systemic inflammation ([@bib197]). Prebiotic plant polyphenols that enrich for *A. muciniphila* showed similar beneficial effects ([@bib9]). The benefits of *A. muciniphila* supplementation have been attributed in part to a bacterial outer membrane protein that interacts with Toll-like receptor 2 and restores gut barrier function ([@bib163]). However, such activity is very likely strain-specific and dependent on the local environment and coassociated microbial peers, since enrichment of *A. muciniphila* has also been observed in diabetic Chinese patients compared with healthy controls ([@bib167]).

Lastly, prebiotic fermentable dietary fiber has been shown to protect mice against HFD-induced metabolic syndrome in a microbiota-dependent manner ([@bib192]; [@bib258]) that was not dependent on SCFAs ([@bib258]) but rather on microbiota-mediated restoration of IL-22 production and enterocyte function ([@bib258]), leading to reduced intestinal permeability ([@bib192]). Interestingly, supplementation of HFD-fed mice with *Bifidobacterium longum* also reversed mucus abnormalities by stimulation of mucin secretion ([@bib192]), suggesting that probiotic and prebiotic treatments may prevent distinct HFD-induced defects in the intestinal mucus layer. Nondigestible fiber has been shown to induce clinically relevant metabolic improvements, coupled with expansion of SCFA-producing enteric microbial species, in Asian patients with T2DM ([@bib252]).

Cardiovascular disease {#s14}
----------------------

Microbial metabolism of dietary choline and carnitine, which comprise a large component of a Western diet, has been shown to increase risk of cardiovascular disease ([@bib93]; [@bib60]). Metabolism of these compounds produces trimethylamine (TMA), which is oxidized in the liver to trimethylamine-*N*-oxide, an amine oxide associated with development of atherosclerosis ([@bib235], [@bib237]; [@bib110]; [@bib254]). The production of TMA is catalyzed by microbial TMA lyase ([@bib110]), and inhibition of this enzyme reduced atherosclerotic plaque development in susceptible *Apoe^−/−^* mice ([@bib237]). Additionally, supplementation of atherosclerosis-prone mice with *A. muciniphila* protected against atherosclerosis development induced by feeding a Western diet ([@bib124]). Indeed, mice harboring high levels of choline-metabolizing bacteria are more susceptible to diet-induced metabolic disease ([@bib174]). Modulation of microbial metabolism through dietary intervention or direct supplementation might therefore provide an effective strategy, either alone or in combination with established therapies, for prevention of cardiovascular diseases.

Autoimmunity {#s15}
------------

The frequency of autoimmune conditions has increased over the past several decades ([@bib159]; [@bib90]; [@bib136]). Molecular mimicry of human antigens by the microbiota is one potential mechanism by which the immune system is reprogrammed, resulting in autoimmune tissue damage ([@bib47]). Variation in microbial LPS immunogenicity has been proposed as one alternative facet that contributes to type 1 diabetes mellitus (T1DM) pathogenesis. In a study of Northern European infants, enrichment of *Bacteroides* spp., particularly *Bacteroides dorei*, was observed in the first three years of life in Finnish and Estonian infants, who exhibit a high prevalence of T1DM compared with Russian infants ([@bib228]). Within this cohort, a positive correlation between the abundance of these bacteria at the phylum level and serum insulin autoantibody levels was observed. This association was attributable to the unique structure of LPS from genus *Bacteroides* that inhibited immune stimulation induced by *Escherichia coli* LPS, which the authors suggest might interfere with normal immune education and increase susceptibility to autoimmunity ([@bib228]). In an independent human study, intestinal microbiota alterations, including loss of bacterial diversity, preceded the onset of metabolic symptoms associated with T1DM ([@bib114]). Additionally, antibiotic-induced dysbiosis altered microbial lipid metabolism and suppressed enteric Th17 and T reg cell populations, leading to increased incidence of T1DM-like disease in nonobese diabetic mice ([@bib130]).

Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory condition that manifests in joint damage. The observation that GF mice are protected from development of experimental arthritis ([@bib241]) suggests a possible role for the microbiome in the pathogenesis of this disease. Patients with RA show expansion of enteric *Prevotella copri* ([@bib186]), and autoantigens in these patients exhibit high homology to *Prevotella*-associated peptides ([@bib161]). Molecular mimicry of RA-associated antigens by the gut microbiota has also been reported in a metagenomic study of RA patients ([@bib251]). However, whether precision editing of the microbiota could alleviate clinical symptoms in patients with RA remains to be elucidated.

Gut microbiota perturbation has also been described in adult ([@bib33]) and pediatric ([@bib222]) patients with MS. In pediatric MS patients, bacterial microbiota richness was positively associated with circulating pro-inflammatory Th17 cells, whereas the relative abundance of SCFA-producing *Bacteroidetes* inversely correlated with systemic inflammatory markers ([@bib221]). GF mice humanized with fecal microbiota from MS patients developed more severe experimental autoimmune encephalomyelitis associated with lower frequencies of T reg cells ([@bib33]). These initial observations implicate the gut microbiome in disease pathogenesis, but additional studies are necessary to delineate the specific microbial strains and products that confer these phenotypes.

Gut microbiota in cancer immunotherapy {#s16}
======================================

Recent evidence has emphasized the importance of enteric microbiota in modulating response to various forms of cancer immunotherapy ([@bib179]; [@bib256]). Cancer patients who responded to anti--programmed cell death protein 1 (PD1) therapy have been shown to harbor more diverse gut microbiota compared with nonresponders ([@bib81]; [@bib178]), who were consistently depleted for bacterial taxa generally associated with health, including *Akkermansia*, *Faecalibacterium*, and *Bifidobacterium* ([@bib81]; [@bib139]; [@bib178]). Improved efficacy of anti-PD1 treatment, with increased antitumor T cell responses, was seen in mice transplanted with fecal microbiota from responding patients ([@bib139]) and in mice supplemented with bacterial taxa depleted in nonresponders ([@bib178]). Although preliminary, these observations suggest that the gut microbiota might offer the opportunity to identify patients who are more likely to respond to treatment, to enhance existing therapeutics, and to develop novel therapeutic strategies.

The microbiome as therapeutic target {#s17}
====================================

Given the tight interplay between enteric microbial symbionts and host immunity, efforts have focused on implementing various strategies targeting the gut microbiota to manage or prevent chronic inflammatory disease. Clinical approaches to modify gut microbiota generally focus on depleting overabundant members or overall microbial load using antibiotics or antifungal agents, modulation through diet manipulation, or supplementation with live microbes (single or mixed species). More recently, fecal microbial transplantation (FMT) has been used in a range of infectious, neurological, and GI conditions, with promising outcomes. Although antimicrobial drugs are not generally considered appropriate for long-term management of chronic conditions, given the need for repeat dosing and concerns about emergence of antimicrobial resistance, early data indicate that administration of antimicrobial drugs, as a means to perturb pathogenic microbiomes before FMT or microbial supplementation, enhances engraftment of beneficial species and improves treatment efficacy ([@bib106]).

Dietary interventions {#s18}
---------------------

Although diet strongly shapes the composition and function of the gut microbiota, only a small number of controlled clinical dietary intervention studies targeting the human gut microbiota have been reported ([@bib46]; [@bib20]; [@bib217]). Recently, a diet rich in fiber was shown to significantly improve glucose control and promote a healthier metabolic profile in T2DM patients ([@bib252]). Other studies showed marked interindividual variation in postprandial glycemic responses after consumption of identical meals ([@bib247]). Consideration of microbial composition alongside known T2DM risk factors (e.g., body mass index, fasting glucose levels) enabled accurate glucose response prediction, thus allowing design of more effective, personalized diets for improved glycemic control ([@bib247]).

Multispecies microbial supplements {#s19}
----------------------------------

Despite encouraging evidence from animal models in which inflammatory conditions were successfully treated via gut microbiota manipulation ([Table 2](#tbl2){ref-type="table"}), data from human trials is less conclusive. Findings from recent work showed that the ability of an introduced microbe to successfully colonize the gut depends on the structure of the resident gut microbiota ([@bib250]; [@bib257]), a factor that has so far been overlooked in microbial intervention--based clinical trials and that might explain discrepancies in animal models and human trials.

###### Evidence for gut microbiota modulation strategies in preventing chronic inflammatory conditions derived from animal models

  Bacterial strain                                                                                                                  Chronic inflammatory condition
  --------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------
  *A. muciniphila*                                                                                                                  Ameliorates HFD-induced obesity and insulin resistance ([@bib61]; [@bib163])
  Protects against atherosclerosis by decreasing gut permeability and preventing endotoxemia-induced inflammation ([@bib124])       
  Improves efficacy of anti-cancer immunotherapy ([@bib178])                                                                        
  *B. fragilis*                                                                                                                     Restores the integrity of the intestinal barrier and ameliorates autistic-like behavior ([@bib88])
  Suppresses neuro-inflammation in experimental model of MS ([@bib234])                                                             
  *B. adolescentis*                                                                                                                 Ameliorates HFD-induced colitis ([@bib127])
  *Bifidobacterium animalis* spp. *lactis*                                                                                          Restores the integrity of the intestinal barrier, thus reducing bacterial translocation and insulin sensitivity ([@bib6])
  *B. animalis* spp. *lactis* and LGG                                                                                               Improves HFD-induced obesity and insulin resistance ([@bib3])
  *B. longum*                                                                                                                       Reduces anxiety-like behavior in a mouse model of chemically induced colitis ([@bib15])
  Restores the integrity of colonic mucus layer impaired by HFD ([@bib192])                                                         
  *Bifidobacterium pseudocatenulatum*                                                                                               Reduces weight gain, body fat, fasting glucose, and insulin resistance in mice with HFD-induced obesity ([@bib252])
  *Christensenella minuta*                                                                                                          Reduces weight gain in mice inoculated with obese human fecal samples ([@bib80])
  *C. scindens*                                                                                                                     Protects against antibiotic-induced *C. difficile* colitis ([@bib26])
  *F. prausnitzii*                                                                                                                  Alleviates inflammation in chemically induced models of colitis ([@bib204]; [@bib168]; [@bib22])
  *L. johnsonii*                                                                                                                    Provides airway protection against allergen challenge and respiratory virus infection ([@bib72]; [@bib67])
  *L. murinus*                                                                                                                      Protects from dextran sodium sulfate--induced colitis by promoting increase in T reg cells in the colon ([@bib213])
  *L. plantarum*                                                                                                                    Recovers growth stunting in juvenile GF mice associated with somatotropic axis signaling ([@bib193])
  Lowers fasting blood glucose and triglyceride levels ([@bib220])                                                                  
  *L. reuteri*                                                                                                                      Restores social behavior in offspring of dams fed HFD ([@bib27])
  Restores despair behavior induced by exposure to chronic stress via suppression of tryptophan/kynurenine metabolism ([@bib138])   
  *L. reuteri*, *L. murinus*, and *Lactobacillus taiwanensis*                                                                       Attenuates intestinal inflammation in experimental model of colitis ([@bib116])
  LGG                                                                                                                               Ameliorates ASD-like behavior by modulating the expression of GABA receptors in the brain ([@bib21])
  *Lactobacillus sakei*                                                                                                             Improves HFD-induced obesity and hyperglycemia by reducing inflammation and increasing the expression of colon tight junction proteins ([@bib129])

Nonetheless, intervention with a multispecies consortium of bacteria was shown to be effective in the induction and maintenance of remission in patients with UC ([@bib142]; [@bib207]), but not in those with CD ([@bib64]). Four months of daily supplementation with the same consortium led to significant improvements in fatty liver disease severity, reductions in body mass index, and increases in glucagon-like peptide levels in children with obesity ([@bib4]). Meta-analysis of intervention trials in which various combinations of bacterial strains were administered to adults with T2DM showed moderate improvements in hyperglycemia ([@bib182]). Moreover, probiotic supplementation during the first 27 d of life reduced risk of islet autoimmunity in a large multicenter prospective cohort study of children at high genetic risk for T1DM, compared with no supplementation or supplementation later in infancy ([@bib226]).

Reduced allergic sensitization was also demonstrated in a meta-analysis of randomized trials of early-life oral microbial interventions ([@bib59]). Additionally, in a recent follow up of a trial in which children with peanut allergies were randomized to receive either placebo or oral peanut immunotherapy combined with daily *L. rhamnosus GG* (LGG) for 18 mo, 67% of children in the immunotherapy/probiotic group remained desensitized to peanuts 4 yr after the intervention compared with 4% in the placebo group ([@bib89]). This observation provides promising results for the long-term efficacy of a combined intervention approach in preventing food allergies; however, as the trial lacked control groups that received either oral immunotherapy or microbial supplementation alone, it remains to be determined whether the observed beneficial effect is attributable to the immunotherapy, the microbial supplementation, or both. Nevertheless, these observations are encouraging and warrant further controlled trials.

Despite promising outcomes of early-life oral microbial supplementation on reduction of atopic sensitization in children, trials have not shown benefits on development of atopic asthma or wheeze ([@bib59]). A recent study examining the effect of early-life (birth to 6 mo of age) LGG supplementation in infants at high risk for asthma found no significant effect of LGG on the development of asthma at 3 yr of age ([@bib29]). However, a subsequent analysis showed that LGG supplementation partially abrogated delayed gut microbiota bacterial diversification and resolved metabolic dysfunction observed in placebo-supplemented high-risk infants ([@bib58]). Furthermore, the associated products of LGG-supplemented fecal microbiomes induced significantly more T reg cells ex vivo. However, LGG colonization and associated benefits of metabolic reprogramming were not sustained ([@bib58]), perhaps suggesting the need for longer-term or earlier (e.g., during pregnancy) intervention or use of a multispecies microbial cocktail with enhanced capacity for competitive colonization of the neonatal gut to achieve long-term efficacy. Despite the negative outcome of this trial, it verifies the plastic nature of the early-life gut microbiome, demonstrates that microbial supplementation is safe and well tolerated in infancy, and provides encouraging data suggesting that gut microbiome--mediated metabolism may be reengineered to promote induction of immune tolerance.

Intervention studies involving live microbial supplementation have shown encouraging results, although more attention to microbial strain selection based on functional attributes, defined timing or duration of supplementation, and/or tailoring of the supplemented organisms to the endogenous gut microbiome of the recipient may significantly improve efficacy in future studies. Ongoing studies are focused on understanding the basis of microbe--microbe interactions in order to identify discrete gut microbiomes that more readily respond to specific microbial interventions.

There is also a great need for tailored interventions that consider the microbiological individuality of the recipient. Such approaches are likely to result in a transition away from historically used probiotic strains, which are frequently poorly adapted to the enteric microenvironment, toward personalized multispecies microbial consortia sourced from healthy human enteric ecosystems. To further enhance efficacy of microbial supplementation, nutritional support in the form of targeted dietary modifications, tailored to the specific substrate requirements of the supplemented microbes, should also be considered. Such an integrated approach to microbiome-based therapeutics ([Fig. 4](#fig4){ref-type="fig"}), built on independent observations in the field of gut microbiome research, may offer more effective, predictable, and sustainable microbial restitution in cases of chronic disease in which microbiome perturbation and functional gene loss are prominent features.

![**A strategic framework for a personalized integrated approach to microbiome manipulation.** Due to microbial heterogeneity across populations, personalized nutrition in combination with the administration of live, functionally defined microbial strains to reengineer microbiome composition, functional gene capacity, and metabolic output may prove most effective in rehabilitating perturbed gut microbiomes for effective disease prevention or management.](JEM_20180448_Fig4){#fig4}

FMT {#s20}
---

FMT has proven effective in \>90% of patients with recurrent antibiotic-resistant *C. difficile* infection ([@bib227]). The success rate of FMT administration for other chronic intestinal inflammatory conditions such as IBD, however, is more modest, with clinical remission being less predictable ([@bib44]). More recently, FMT has been applied to chronic inflammatory conditions affecting organs distal to the GI tract. A small trial of children aged 7--16 yr diagnosed with ASD showed that FMT improved both GI and ASD behavioral symptoms, in concert with changes to their gut microbiota composition, which was sustained 2 mo after intervention ([@bib102]). In a separate study, FMT from lean donors improved insulin sensitivity in obese men with metabolic syndrome, and this improvement was linked to changes in plasma metabolites, in particular increased gamma-aminobutyric acid (GABA), tryptophan, and phenylalanine ([@bib111]). GABA has been associated with regulation of metabolism in mouse models ([@bib141]) and with successful (albeit short-lived) engraftment of lean-donor FMT and improved health in men with metabolic syndrome ([@bib111]), suggesting a role for GABA in glucose metabolism in humans. Studies focused on understanding the dynamics of donor microbiota colonization following single-donor FMT have demonstrated varying degrees of microbial transfer in different recipients ([@bib126]), which was later shown to depend on the abundance and composition of bacteria in both the donor and pre-FMT recipient ([@bib201]). These results suggest that, as for other organ transplants, gut microbiome compatibility is an important, but currently overlooked, factor that needs to be considered in future trials.

The risks associated with FMT are not completely defined. Donor material is prescreened for known infectious agents, but there remains a risk of transferring to the recipient phenotypes that are clinically silent in the donor. For this reason alone, the FMT approach may not be feasible for infants at high risk for developing chronic conditions, and alternative interventions with quality-controlled microbes from human sources may prove more appropriate for such vulnerable populations. In a recent proof-of-principle study, the gut microbiota of cesarean section--delivered infants was manipulated to more closely resemble that of vaginally delivered newborns by swabbing the neonate with gauze inoculated with the mother's vaginal microbiota ([@bib54]). These results demonstrate that vaginal microbes typically underrepresented in babies delivered by cesarean section can be partially and safely restored at birth, although the long-term health consequences of these interventions remain to be determined.

Microbial transplantation is proving useful as a means of manipulating the gut microbiome for management or prevention of certain illnesses or disorders, although many more well-designed studies are needed. More importantly, early studies have provided insights into the critical organisms and biomolecules that mediate efficacy and those that impede it. As the field progresses, it is likely that this approach will be surpassed by more precise and integrated multispecies microbial/diet-based interventions tailored to the individual and their specific microbial perturbation ([Fig. 4](#fig4){ref-type="fig"}).

Summary and perspectives {#s21}
========================

Sequencing, mass spectrometry, and a variety of in vitro and in vivo model approaches have led to the observation that gut microbiome perturbation is evident in a variety of human diseases that manifest either locally in the gut or remotely at discrete organ and mucosal sites. In specific cases, gut microbiome perturbations are evident years in advance of disease development, offering biomarkers for early detection of disease risk and opportunities for preventive interventions. Paramount to all of these observations is the increasing evidence for microbial causality in disease development and identification of specific mechanisms of pathogenesis, the latter identifying novel microbial targets for therapeutic development. Positive results have been observed for some disease indications following efforts to rehabilitate perturbed gut microbiota via dietary intervention, microbial supplementation, or FMT. These efforts provide proof of principle that the gut microbiome represents a viable therapeutic target, with the opportunity to develop more refined and integrated approaches for disease management, prevention, or cure. Despite the promise, the gut microbiome field has much to do, including large and longitudinal integrative studies of humans to include all (bacterial, fungal, and viral) members of the gut microbiome and their products in the context of objective immune and physiological measurements and clinical outcomes. Complementing such investigations with mechanistic studies is critical to move the field beyond description and toward a molecular understanding of how microbe--microbe--host interactions influence human health over the course of life and is key to realizing the full potential of the field.
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